Skip to main content

Table 1 Complement activation in plasma from patients with Crohn's disease (CD), patients with ulcerative colitis (UC) and healthy subjects (HS) before and after 1, 6 and 12 weeks high-dose treatment with prednisolone.

From: Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis

  before treatment after 1 week after 6 weeks after 12 weeks
  Number of patients Number of patients Number of patients Number of patients
CD 18 18 18 18
UC 18 18 18 16
HS 38 -- -- --
C3-AC, alternative % of standard % of standard % of standard % of standard
CD 61.5 (53–82) 51.5 (49–71) 55.5 (49–70) 59 (49–75)
UC 58 (49–78) 49 (49–70) 49 (49–78) 59 (49–70)
HS 49 (49–67) -- -- --
C3-AC, classical % of standard % of standard % of standard % of standard
CD 109 (81–172) 97.5 (39–124) 94.5 (70–141) 99.5 (53–143)
UC 97 (39–148) 88 (58–129) 91 (59–115) 94 (39–160)
HS 82.5 (68–108) -- -- --
MBL-concentration ng/ml ng/ml ng/ml ng/ml
CD 3251 (14 – 6085) 3071 (10 – 4636) 2911 (10 – 5178) 3257 (10 – 4718)
UC 1082 (6 – 3926) 1171 (3 – 4845) 1141 (3 – 4590) 1292 (3 – 4147)
HS 1219 (2 – 3577) -- -- --
MBL-C4-AC % of standard % of standard % of standard % of standard
CD 118 (21–187) 63 (25–192) 62.5 (21–163) 87 (17–192)
UC 54 (12–201) 54 (11–192) 45 (9–163) 55 (12–192)
HS 66.5 (9–162) -- -- --
  1. Median and range (in parenthesis) of alternative and classical pathway-mediated C3-activation capacity(C3-AC), mannan-binding lectin (MBL) concentration, MBL-C4-AC.
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us